Vesnarinone

Vesnarinone (OPC-8212) is an orally active phosphodiesterase 3 (PDE3) inhibitor. Vesnarinone can increase in calcium flux and decrease in potassium flux. Vesnarinone shows dose-dependent positive inotropic activity. Vesnarinone can be used in heart failure research[1][2][3][4].

Product Specifications

CAS Number

[81840-15-5]

Product Name Alternative

OPC-8212

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Vesnarinone.html

Purity

98.58

Solubility

DMSO : 16.67 mg/mL (ultrasonic)

Smiles

O=C1NC2=C(C=C(N3CCN(C(C4=CC=C(OC)C(OC)=C4)=O)CC3)C=C2)CC1

Molecular Formula

C22H25N3O4

Molecular Weight

395.45

Precautions

H302, H315, H319, H335

References & Citations

[1]A Matsumori, et al. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation. 1994 Mar;89 (3) :955-8.|[2]E Cavusoglu, et al. Vesnarinone: a new inotropic agent for treating congestive heart failure. J Card Fail. 1995 Jun;1 (3) :249-57.|[3]K Yoneda, et al. Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells. Cancer Lett. 1998 Nov 13;133 (1) :35-45.|[4]Iain Gardner, et al. A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo. Chem Res Toxicol. 2005 Sep;18 (9) :1384-94.